3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026

The article spotlights three high-yield dividend plays for 2H 2026: Novo Nordisk at a 3.5% yield (aiming to regain GLP-1 market share as its pill uptake outpaces its shot, despite falling GLP-1 prices), Realty Income at a 5% yield (31 straight years of dividend increases across 15,500+ properties), and Enterprise Products Partners at a 5.9% yield (midstream “toll-taker” model with distributable cash flow covering the distribution by ~1.7x). It argues the revenue/earnings pressure for Novo from price declines is intentional and expected to be offset by volume growth. Overall, it frames income durability as the key support—particularly for Realty Income’s conservative credit profile and Enterprise’s reduced oil-price sensitivity.

Analysis

The cleanest signal here is not “high yield,” but which balance sheets are financing real cash flow versus marketing stories. NVO looks like a volume-recovery trade disguised as income: if oral adoption scales, the market may re-rate the multiple before dividend yield matters, but the key variable is payer mix and net price realization. If rebates deepen faster than unit growth, this becomes a classic value trap despite headline demand.

O is a duration trade more than a property call. The upside case is a lower-rate backdrop that stabilizes cap rates and keeps refinancing benign; the downside is that it behaves like a long bond with modest growth, so a sticky 10-year yield can compress the equity story even if operations stay fine. The second-order winner may be industrial/warehouse net lease peers with better growth optionality, while any credit spread widening would hit smaller REITs harder than O.

EPD is the most structurally interesting because it monetizes throughput, not price. Over 6-18 months, North American energy-security capex, LNG buildout, and export re-routing can support volumes even if crude mean-reverts; the risk is not oil, but producer discipline slowing pipe fill rates. Contrarian view: the market may be underestimating how much of the “defensive dividend” pitch is already crowded into these names, while underpricing the relative-value trade of EPD versus more commodity-sensitive energy exposure.

Key Decisions for Investors

• Long EPD vs. short XLE for 3-6 months: isolate fee-based midstream cash flow from commodity beta; thesis breaks if EPD volume growth stalls or producer capex rolls over.
• Small tactical long NVO / short LLY on 1-3 month horizon: play oral GLP-1 share shift; stop if NVO prescription traction fails to inflect or net pricing compresses faster than expected.
• Hold/add O only on rate-stability pullbacks: best entry is if the 10-year yield backs off and REIT spreads stabilize; avoid adding if real rates re-accelerate.
• If you want optionality, use NVO call spreads instead of stock for the next 1-2 quarters: you’re paying for a rerating on adoption data, not underwriting a clean earnings step-up.